- About MEDx
- Technology Centers
- Pharma Solutions
-
CDx/IVD Products
IHC-Based AssaysPCR-Based AssaysNGS-Based AssaysMore AssaysCustomized Assays - Clinical Testing
- Quality Systems
- Events
- Contact Us
The c-MET gene encodes a tyrosine kinase-type receptor, and its ligand is hepatocyte growth factor (HGF). c-MET is the only known HGF high-affinity receptor. HGF activates c-MET after binding to c-MET, which causes cell proliferation, migration, differentiation and morphological changes and plays an important physiological function. Abnormal activation of HGF/c-MET signaling pathway can promote the occurrence, development and metastasis of various malignant tumors. It has been demonstrated that c-MET gene is mutated, amplified and overexpressed in a variety of cancers such as lung cancer, breast cancer, head and neck squamous cell carcinoma, liver cancer, esophageal cancer, gastric cancer, and colorectal cancer.
This product uses immunohistochemical (IHC) method to qualitatively detect the level of c-MET protein expression in cancer tissues.
IHC
Product record number Susu Machinery No. 20180518
Good specificity and high sensitivity; accurate positioning, combined morphology and function; reliable results, easy to analyze.
Pan-solid tumors, mainly lung cancer
If you have any of the following needs, feel free to contact us or email us at inquiry@MEDxTMC.net . We will reply within 24 hours.
1. Customized or bulk orders of IVD/CDx products.
2. Get a quote for IVD/CDx products
3. Become our distributor
4. Get customized pharmaceutical service solutions
5.Learn more about our technology and R&D
